Novo Nordisk received positive feedback from CHMP for treating idiopathic short stature in children with the once-a-week medication Sogroya® in Europe.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.